Strongbridge Biopharma plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Strongbridge Biopharma plc
Deal Watch: Roche To Try Pieris’s Anticalins In Respiratory, Ophthalmic Indications
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.
More Competition Coming To Cushing's Market
Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space
Keeping Track: Recent NDA Submissions Range From Acute Agitation To Von Hippel-Lindau Disease
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
- Other Names / Subsidiaries
- BioPancreate Inc., Cortendo AB
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.